25H1 毛利率基本持平，净利率受非经常性收益大幅提高。盈利能力：25H1 毛利率59.67%（同 比-0.1pct），归母净利率10.6%（同比-4.4pct）。费用率：销售费用率40.0%（同比-0.3pct）；管理费用 率8.22%（同比+0.3pct）；研发费用率1.88%（同比-0.1pct）。 医美体外并入与轻医美机构带动增长。25H1 医美营收13.33 亿元，同降6.1%，占比47.8%，毛利率 54.54%。截至24H1 合计有42 家医美机构，其主营医美机构米兰柏羽、高一生、晶肤医美、韩辰医美、 武汉五洲、郑州集美分别拥有6/1/31/2/1/1 家机构。手术类医美收入·1.73 亿元，占比13.0%，占比下降； 非手术类医美11.60 亿元，占比上升至87.0%。公司各大医美品牌专注不同领域，在当地拥有较高知名 度与市占率，规模优势初具。 时尚女装品牌形象全面升级，电商渠道快速发展。25H1 时尚女装业务收入9.88亿元，同降2.42%，毛利 率65.15%。其中，线上渠道收入近4.57 亿元，占比46.3%，线上占比大幅提升。渠道方线上线下融合布 局，巩固服装行业领先地位。 公司发布2 ...

Financial Performance - In Q1 2025, the company achieved total revenue of approximately 1.399 billion yuan, a year-on-year decrease of 7.77% [2] - Gross profit margin was 59.72%, an increase of 0.38 percentage points compared to the same period last year [2] - Net profit attributable to shareholders was approximately 61 million yuan, a year-on-year increase of 5.12% [2] - Net profit after deducting non-recurring items was approximately 73 million yuan, a year-on-year decrease of 6.89% [2] - Net cash flow from operating activities was approximately 174 million yuan, a year-on-year decrease of 23.43% [2] - Basic earnings per share were 0.2153 yuan, an increase of 5.13% year-on-year [2] - Return on equity was 3.36% [2] - As of March 31, 2025, total assets were approximately 8.004 billion yuan, a growth of 0.41% from the end of the previous year [3] - Net assets attributable to shareholders were approximately 2.883 billion yuan, an increase of 3.42% from the end of the previous year [3] Business Segment Performance - Medical beauty segment revenue was approximately 670 million yuan, a year-on-year decrease of 9.22% [3] - Medical beauty segment gross profit was approximately 369 million yuan, a decrease of 8.58% year-on-year, with a gross profit margin of 55.05% [3] - Women's clothing segment revenue was approximately 504 million yuan, a year-on-year decrease of 5.74% [3] - Women's clothing segment gross profit was approximately 325 million yuan, with a gross profit margin of 64.51%, an increase of 0.15 percentage points year-on-year [3] - Infant and child segment revenue was approximately 221 million yuan, a year-on-year decrease of 8.52% [3] - Infant and child segment gross profit was approximately 137 million yuan, with a gross profit margin of 62.28%, an increase of 1.78 percentage points year-on-year [3] Brand Performance - Milan Baiyu achieved revenue of approximately 302.62 million yuan, a year-on-year decrease of 8.74% [4] - Jingfu Medical achieved revenue of approximately 125.20 million yuan, a year-on-year increase of 1.13% [4] - Hanchen Medical achieved revenue of approximately 97.93 million yuan, a year-on-year decrease of 1.43% [4] - Wuhan Wuzhou achieved revenue of approximately 47.55 million yuan, a year-on-year decrease of 15.11% [4] - Changsha Yamei achieved revenue of approximately 40.70 million yuan, a year-on-year decrease of 28.61% [4] - Zhengzhou Jimei achieved revenue of approximately 25.68 million yuan, a year-on-year decrease of 16.26% [4] Inventory and Operations - As of Q1 2025, total inventory for women's clothing was approximately 646 million yuan, a decrease of 4.75% from the end of the previous year [5] - The net amount of inventory goods was approximately 512 million yuan, a decrease of 7.45% from the end of the previous year [5] - The structure of inventory improved in Q1 2025 [5]

Core Viewpoint - The medical beauty industry is facing significant challenges, with "difficult operations" becoming a consensus within the sector [1]. Company Performance - Langzi Medical Beauty Group, despite being a listed large chain, is struggling with performance growth. In 2024, the company reported revenue of 5.691 billion yuan, a slight decline from the previous year, and in Q1 2025, revenue further decreased to 1.399 billion yuan, down 7.77% year-on-year. The net profit after deducting non-recurring items was 73.2755 million yuan, a decrease of 6.89% [2]. - The company initially focused on mid-to-high-end women's clothing but faced challenges due to the rise of e-commerce and foreign luxury brands. Despite attempts to diversify into children's clothing, revenue and profit continued to decline [4][5]. - From 2013 to 2015, revenue fell from 1.379 billion yuan to 1.144 billion yuan, and net profit dropped from 204 million yuan to 33 million yuan [5]. Strategic Expansion - Langzi entered the medical beauty market in 2016 through strategic investments and acquisitions, including the purchase of the Korean medical beauty service group DMG and several brands [6][12]. - The company adopted an aggressive acquisition strategy, acquiring multiple medical beauty institutions from 2017 to 2024, aiming to become a leading player in the domestic medical beauty sector [6][8]. Revenue Contribution - By 2024, the medical beauty segment contributed 49% of Langzi's revenue and 45% of its gross profit, surpassing the original women's clothing and children's business contributions [8]. - Despite the successful transition to medical beauty, the expected high growth has not materialized, with the medical beauty segment's revenue growth only at 3.47% year-on-year in 2024 [9]. Profitability Concerns - The gross profit margin for the medical beauty business was 54.42%, lower than the women's clothing (63.45%) and children's business (61.76%) [9]. - The company’s net profit in 2024 was only slightly higher than in 2013, indicating that the transition has not significantly improved profitability [9][10]. Financial Risks - Langzi's goodwill reached 1.781 billion yuan in 2024, accounting for 64% of its net assets, raising concerns about potential impairment risks [13]. - The company faces short-term debt pressures, with 1.323 billion yuan in short-term debt and only 555 million yuan in cash, resulting in a cash-to-short-term-debt ratio of 0.42 [15]. Market Outlook - The medical beauty industry is experiencing intensified competition and slowing growth, compounded by economic challenges and underwhelming consumer recovery [17].